Government-Owned Inventions; Availability for Licensing, 50768-50769 [2010-20274]
Download as PDF
<![CDATA[
50768
Federal Register / Vol. 75, No. 158 / Tuesday, August 17, 2010 / Notices
account for twenty percent of primary
brain tumors and fifty percent of
astrocytomas. These indications are
designated as rare diseases as there is an
annual 2–3 newly diagnosed cases of
glioblastoma per 100,000 people in the
United States whereas the astrocytoma
incidence rate is 1.22 cases per 100,000
for individuals aged 0–19 years in the
United States.
Applications:
• Blood based diagnostic assays.
• Assay for clinicians to choose
effective treatments.
• Therapy to treat human
glioblastoma.
Advantages:
• Non-invasive diagnostics.
• Easy, ready to use assays.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Market: Brain cancer market was
worth an estimated $1,094 million in
2009 and expected to reach $1.3 billion
by 2016.
Inventor: Zheng-gang Liu (NCI).
Patent Status: PCT Patent Application
No. PCT/US2010/36394 filed 27 May
2010 (HHS Reference No. E–178–2009/
0–PCT–02).
Licensing Status: Available for
licensing.
Licensing Contact: Jennifer Wong;
301–435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute, Cell and
Cancer Biology Branch, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize this technology. Please
contact John Hewes, Ph.D. at 301–435–
3131 or hewesj@mail.nih.gov for more
information.
jdjones on DSK8KYBLC1PROD with NOTICES
Inflammatory Genes and MicroRNA–21
as Biomarkers for Colon Cancer
Prognosis
Description of Invention: Colon
adenocarcinoma is the leading cause of
cancer mortality world-wide and
accounts for approximately 50,000
deaths annually in the United States.
Adjuvant therapies improve survival for
stage III colon cancer patients; however,
it remains controversial if stage II
patients should be given these therapies.
Some stage II patients will benefit from
therapy (such as patients with
undetectable micro-metastases where
surgery will not be curative); but
therapy for others will harm quality of
life with little therapeutic benefit (such
as patients where surgery removed all
cancerous tissue and therefore do not
need additional therapy). Thus, there is
a need to for biomarkers capable of
accurately identifying high risk, stage II
VerDate Mar<15>2010
15:16 Aug 16, 2010
Jkt 220001
patients that are suitable for therapeutic
intervention.
The investigators have identified an
inflammatory gene and microRNA
biomarker portfolio that can predict
aggressive colon cancer, colon cancer
patient survival, and patients that are
candidates for adjuvant therapy. These
biomarkers provide clinicians with a
powerful tool to diagnose colon cancer
patients and chose effective treatment
methods.
Applications:
• Method to predict aggressive form
of colon cancer, especially in stage II
cancer patients.
• Method to determine appropriate
colon cancer patients for adjuvant
therapy.
• Diagnostic arrays.
Advantages:
• Rapid, easy to use arrays to
accurately predict colon cancer and
patients suitable for adjuvant therapy.
• Method to stratify colon cancer
patients for adjuvant therapy to
minimize negative side effects.
• Method to identify stage II patients
that are likely to have undetectable
micro-metastases.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Market:
• Global cancer market is worth more
than eight percent of total global
pharmaceutical sales.
• Cancer industry is predicted to
expand to $85.3 billion by 2010.
Inventors: Curtis C. Harris and Aaron
J. Schetter (NCI).
Relevant Publication: AJ Schetter et
al. MicroRNA expression profiles
associated with prognosis and
therapeutic outcome in colon
adenocarcinoma. JAMA. 2008 Jan
30;299(4):425–436. [PubMed:
18230780].
Patent Status: PCT Application No.
PCT/US09/058425 filed 25 Sep 2009,
which published as WO/2010/036924
on 01 Apr 2010 (HHS Reference No. E–
314–2008/0–PCT–02).
Licensing Status: Available for
licensing.
Licensing Contact: Jennifer Wong;
301–435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The NCI Laboratory of Human.
Carcinogenesis is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize cancer biomarkers and
therapeutic targets. Please contact
Curtis_Harris@nih.gov for more
information.
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
Dated: August 11, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2010–20277 Filed 8–16–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUMMARY:
A Novel Scaffold for Multivalent
Display of Ligands
Description of Invention: Multivalent
interactions are important in cell
attachment, wound healing and immune
responses. Such interactions are
associated with cancer metastasis, blood
clotting and the generation of antibodies
from a vaccination. Mimicking
multivalent interactions on a synthetic
scaffold is challenging especially when
large numbers of ligands (such as 5 or
more) need to be displayed. There are
numerous synthetic scaffolds that have
been developed, but there are significant
limitations that remain.
Scientists at the NIH have designed a
novel multivalent scaffold that can
display anywhere from 1 to 200 ligands.
This system allows different types of
ligands to be displayed in a controlled,
spatially-addressable manner. This
system uses peptide nucleic acids
(PNAs) containing g-substituted side
E:\FR\FM\17AUN1.SGM
17AUN1
Federal Register / Vol. 75, No. 158 / Tuesday, August 17, 2010 / Notices
chains. PNAs are synthetic molecules
that possess the bases derived from
DNA. This invention could
revolutionize the way in which
multivalent display is used in research
as well as help make vaccinations or
prevent disease.
Applications:
• Controlled interactions ensure only
a single stoichiometry is attained.
• Simple access to a wide range of
multivalent platforms.
Development Status: Early stage.
Inventors: Daniel Appella et al.
(NIDDK).
Patent Status: U.S. Provisional
Application No. 61/333,442 filed 11
May 2010 (HHS Reference No. E–129–
2010/0–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: Charlene Sydnor,
PhD; 301–435–4689;
sydnorc@mail.nih.gov.
Collaborative Research Opportunity:
The NIDDK Laboratory of Bioorganic
Chemistry is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this novel scaffold or to
collaborate on related laboratory
interests. Please contact Marguerite J.
Miller at 301–496–9003 and/or
millermarg@niddk.nih.gov for more
information.
jdjones on DSK8KYBLC1PROD with NOTICES
N-Methanocarba Adenosine Derivatives
and Their Dendrimer Conjugates as A3
Receptor Agonists
Description of Invention: This
technology relates to specific (N)methanocarba adenine nucleosides that
have been developed and dendrimers
that connect these compounds to create
molecules with multiple targets.
Dendrimers are essentially repeated
molecular branches presenting the core
receptor-binding molecules. The
compounds synthesized function as
agonists and antagonists of a receptor of
the G-protein coupled receptor (GPCR)
superfamily. In particular, the receptors
of interest for this invention include A3
adenosine receptors and agonists and
antagonists of P2Y receptors, such as
P2Y1 and P2Y14.
Dendrimer conjugates may have one
or more advantages, such as increased
solubility, reduced toxicity, and
improved pharmacokinetic properties.
They can also be used to connect other
types of molecules without affecting the
agonist or antagonists properties. For
instance, molecules such as those used
for imaging or tracing can be added.
Dendrimers can also be used to link
VerDate Mar<15>2010
15:16 Aug 16, 2010
Jkt 220001
more than one type of agonist or
antagonist to confer multiple
functionalities. This technology
provides a novel mechanism to treat a
number of disorders related to
dysregulation of A3 adenosine receptors.
Applications:
• Cardiac arrhythmias or ischemia
• Inflammation
• Stroke
• Diabetes
• Asthma
• Cancer
• Imaging
Development Status: Research
quantities of compounds have been
synthesized and tested for receptor
selectivity.
Inventors: Kenneth A Jacobson and
Dilip K. Tosh (NIDDK).
Patent Status:
U.S. Provisional Application No. 61/
266,084 filed 02 Dec 2009 (HHS
Reference No. E–049–2010/0–US–01).
U.S. Provisional Application No. 61/
313,961 filed 15 Mar 2010 (HHS
Reference No. E–049–2010/1–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: Steven Standley,
PhD; 301–435–4074;
sstand@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Diabetes and
Digestive and Kidney Diseases,
Laboratory of Bioorganic Chemistry,
Molecular Recognition Section, is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize this
technology. Please contact Dr. Kenneth
Jacobson at kajacobs@helix.nih.gov for
more information.
Species-Independent A3 Adenosine
Receptor Agonists Which May Be
Useful for Treating Ischemia,
Controlling Inflammation, and
Regulating Cell Proliferation
Description of Invention: This
invention claims species-independent
agonists of A3AR, specifically (N)methanocarba adenine nucleosides and
pharmaceutical compositions
comprising such nucleosides. The A3
adenosine receptor (A3AR) subtype has
been linked with helping protect the
heart from ischemia, controlling
inflammation, and regulating cell
proliferation. Agonists of the human
A3AR subtype have been developed that
are also selective for the mouse A3AR
while retaining selectivity for the
human receptor. This solves a problem
for clinical development because animal
model testing is important for pre-
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
50769
clinical validation of drug function.
Novel agonists have been made that
exhibit as much as 6000x selectivity for
A3 versus A1 in humans while retaining
at least 400x selectivity for A3 versus A1
in mice. In addition, the molecules of
the invention exhibit very low
nanomolar affinity. This innovation will
not only facilitate moving A3 agonists
into the clinical phase of drug
development by being more amenable to
animal studies, but also provide much
greater selectivity in humans, and
thereby potentially fewer side effects
than drugs currently undergoing clinical
trials.
Applications:
• Cardiac arrhythmias or ischemia
• Inflammation
• Stroke
• Diabetes
• Asthma
• Cancer
Development Status: Research
quantities of compounds have been
synthesized and tested for receptor
selectivity.
Inventors: Kenneth A. Jacobson and
Artem Melman (NIDDK).
Publication: A Melman et al. Design
of (N)-methanocarba adenosine 5’uronamides as species-independent A3
receptor-selective agonists. Bioorg Med
Chem Lett. 2008 May 1;18(9):2813–
2819. [PubMed: 18424135].
Patent Status: PCT Application No.
PCT/US09/38026 filed 24 Mar 2009,
which published as WO 2009/123881
on 08 Oct 2009 (HHS Reference No. E–
140–2008/0–PCT–02).
Licensing Status: Available for
licensing.
Licensing Contact: Steven Standley,
Ph.D.; 301–435–4074;
sstand@mail.nih.gov.
Collaborative Research Opportunity:
The NIDDK Laboratory of Bioorganic
Chemistry is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize A3 Adenosine Receptor
Agonists. Please contact Marguerite J.
Miller at 301–496–9003 or
millermarg@niddk.nih.gov for more
information.
Dated: August 11, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2010–20274 Filed 8–16–10; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\17AUN1.SGM
17AUN1
]]>Agencies
[Federal Register Volume 75, Number 158 (Tuesday, August 17, 2010)]
[Notices]
[Pages 50768-50769]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-20274]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
A Novel Scaffold for Multivalent Display of Ligands
Description of Invention: Multivalent interactions are important in
cell attachment, wound healing and immune responses. Such interactions
are associated with cancer metastasis, blood clotting and the
generation of antibodies from a vaccination. Mimicking multivalent
interactions on a synthetic scaffold is challenging especially when
large numbers of ligands (such as 5 or more) need to be displayed.
There are numerous synthetic scaffolds that have been developed, but
there are significant limitations that remain.
Scientists at the NIH have designed a novel multivalent scaffold
that can display anywhere from 1 to 200 ligands. This system allows
different types of ligands to be displayed in a controlled, spatially-
addressable manner. This system uses peptide nucleic acids (PNAs)
containing [gamma]-substituted side
[[Page 50769]]
chains. PNAs are synthetic molecules that possess the bases derived
from DNA. This invention could revolutionize the way in which
multivalent display is used in research as well as help make
vaccinations or prevent disease.
Applications:
Controlled interactions ensure only a single stoichiometry
is attained.
Simple access to a wide range of multivalent platforms.
Development Status: Early stage.
Inventors: Daniel Appella et al. (NIDDK).
Patent Status: U.S. Provisional Application No. 61/333,442 filed 11
May 2010 (HHS Reference No. E-129-2010/0-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Charlene Sydnor, PhD; 301-435-4689;
sydnorc@mail.nih.gov.
Collaborative Research Opportunity: The NIDDK Laboratory of
Bioorganic Chemistry is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize this novel scaffold or to collaborate on
related laboratory interests. Please contact Marguerite J. Miller at
301-496-9003 and/or millermarg@niddk.nih.gov for more information.
N-Methanocarba Adenosine Derivatives and Their Dendrimer Conjugates as
A3 Receptor Agonists
Description of Invention: This technology relates to specific (N)-
methanocarba adenine nucleosides that have been developed and
dendrimers that connect these compounds to create molecules with
multiple targets. Dendrimers are essentially repeated molecular
branches presenting the core receptor-binding molecules. The compounds
synthesized function as agonists and antagonists of a receptor of the
G-protein coupled receptor (GPCR) superfamily. In particular, the
receptors of interest for this invention include A3
adenosine receptors and agonists and antagonists of P2Y receptors, such
as P2Y1 and P2Y14.
Dendrimer conjugates may have one or more advantages, such as
increased solubility, reduced toxicity, and improved pharmacokinetic
properties. They can also be used to connect other types of molecules
without affecting the agonist or antagonists properties. For instance,
molecules such as those used for imaging or tracing can be added.
Dendrimers can also be used to link more than one type of agonist or
antagonist to confer multiple functionalities. This technology provides
a novel mechanism to treat a number of disorders related to
dysregulation of A3 adenosine receptors.
Applications:
Cardiac arrhythmias or ischemia
Inflammation
Stroke
Diabetes
Asthma
Cancer
Imaging
Development Status: Research quantities of compounds have been
synthesized and tested for receptor selectivity.
Inventors: Kenneth A Jacobson and Dilip K. Tosh (NIDDK).
Patent Status:
U.S. Provisional Application No. 61/266,084 filed 02 Dec 2009 (HHS
Reference No. E-049-2010/0-US-01).
U.S. Provisional Application No. 61/313,961 filed 15 Mar 2010 (HHS
Reference No. E-049-2010/1-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Steven Standley, PhD; 301-435-4074;
sstand@mail.nih.gov.
Collaborative Research Opportunity: The National Institute of
Diabetes and Digestive and Kidney Diseases, Laboratory of Bioorganic
Chemistry, Molecular Recognition Section, is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize this
technology. Please contact Dr. Kenneth Jacobson at
kajacobs@helix.nih.gov for more information.
Species-Independent A3 Adenosine Receptor Agonists Which May
Be Useful for Treating Ischemia, Controlling Inflammation, and
Regulating Cell Proliferation
Description of Invention: This invention claims species-independent
agonists of A3AR, specifically (N)-methanocarba adenine
nucleosides and pharmaceutical compositions comprising such
nucleosides. The A3 adenosine receptor (A3AR)
subtype has been linked with helping protect the heart from ischemia,
controlling inflammation, and regulating cell proliferation. Agonists
of the human A3AR subtype have been developed that are also
selective for the mouse A3AR while retaining selectivity for
the human receptor. This solves a problem for clinical development
because animal model testing is important for pre-clinical validation
of drug function. Novel agonists have been made that exhibit as much as
6000x selectivity for A3 versus A1 in humans
while retaining at least 400x selectivity for A3 versus
A1 in mice. In addition, the molecules of the invention
exhibit very low nanomolar affinity. This innovation will not only
facilitate moving A3 agonists into the clinical phase of
drug development by being more amenable to animal studies, but also
provide much greater selectivity in humans, and thereby potentially
fewer side effects than drugs currently undergoing clinical trials.
Applications:
Cardiac arrhythmias or ischemia
Inflammation
Stroke
Diabetes
Asthma
Cancer
Development Status: Research quantities of compounds have been
synthesized and tested for receptor selectivity.
Inventors: Kenneth A. Jacobson and Artem Melman (NIDDK).
Publication: A Melman et al. Design of (N)-methanocarba adenosine
5'-uronamides as species-independent A3 receptor-selective
agonists. Bioorg Med Chem Lett. 2008 May 1;18(9):2813-2819. [PubMed:
18424135].
Patent Status: PCT Application No. PCT/US09/38026 filed 24 Mar
2009, which published as WO 2009/123881 on 08 Oct 2009 (HHS Reference
No. E-140-2008/0-PCT-02).
Licensing Status: Available for licensing.
Licensing Contact: Steven Standley, Ph.D.; 301-435-4074;
sstand@mail.nih.gov.
Collaborative Research Opportunity: The NIDDK Laboratory of
Bioorganic Chemistry is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize A3 Adenosine Receptor Agonists.
Please contact Marguerite J. Miller at 301-496-9003 or
millermarg@niddk.nih.gov for more information.
Dated: August 11, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-20274 Filed 8-16-10; 8:45 am]
BILLING CODE 4140-01-P
